Lung wash and tumor fluid markers for sarcoma lung metastases
Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas
PHASE2 · University Health Network, Toronto · NCT06815666
This study will test whether lung wash (bronchoalveolar lavage) and tumor fluid biomarkers can indicate how much metastatic soft tissue sarcoma is in the lungs for adults having lung surgery.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto (other) |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06815666 on ClinicalTrials.gov |
What this trial studies
This single-center, Phase II prospective study will collect bronchoalveolar lavage fluid (BALF) and TA samples during routine bronchoscopy at Toronto General Hospital and obtain tissue from lung metastases and adjacent normal lung at the time of resection. Researchers will analyze those fluids and tissues to identify biomarkers and correlate their levels with metastatic burden. Sample collection is performed alongside standard clinical procedures to minimize additional interventions. The goal is to determine whether these biomarkers reliably reflect the extent of lung metastases in soft tissue sarcoma patients.
Who should consider this trial
Good fit: Adults (age ≥18) with diagnosed soft tissue sarcoma who are undergoing resection of a lung lesion and can give informed consent are the intended participants.
Not a fit: Patients who are not undergoing bronchoscopy or lung metastasectomy, or those with a recent other invasive cancer (within 2 years, except treated non-melanoma skin cancer), would not be eligible and may not benefit.
Why it matters
Potential benefit: If successful, the biomarkers could provide a less invasive way to monitor lung metastatic burden and help guide personalized follow-up or treatment decisions.
How similar studies have performed: While BAL fluid biomarkers have been explored in lung cancer and inflammatory lung diseases, applying BALF and TA biomarkers specifically to measure metastatic burden in soft tissue sarcoma is relatively novel and not yet well established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Ability to understand and willingness to sign a written informed consent document 3. Diagnosed with soft tissue sarcoma 4. Undergoing resection of lung lesion as part of standard care Exclusion Criteria: 1\. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years
Where this trial is running
Toronto, Ontario
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Study coordinator: David Shultz
- Email: david.shultz@uhn.ca
- Phone: 416-946-4501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Soft Tissue Sarcoma, Bronchoalveolar Lavage, Bronchoalveolar Lavage Fluid